CRVS News and Press, Corvus Pharmaceuticals Inc. From 07/23/21

At the mid-year mark, our contributors give updates on their picks. We highlight two recent top performers. And stay tuned for next week, where some contributors introduce new ideas with the Double Down or Diversify series. For further details see: SA Marketplace 2021 To...

Cristian Storto Fotografia/iStock via Getty Images The shares of Corvus Pharmaceuticals ([[CRVS]] -0.9%) have reached their lowest level in more than a year after the company announced an end to its late-stage study for mupadolimab in COVID-19, citing the positive impact of vaccines on virus-...

Gainers: China SXT Pharmaceuticals (SXTC) +37%, Trinity Biotech (TRIB) +11%, Moderna (MRNA) +9%, Aptevo Therapeutics (APVO) +9%, Apollo Medical (AMEH) +4%.Losers: FibroGen (FGEN) -45%, Neptune Wellness Solutions (NEPT) -20%, Atossa Therapeutic...

FibroGen (FGEN) -33% after setback for kidney disease therapy in FDA AdCom meetingLiquid Media (YVR) -17% on Q2 earnings releaseATA Creativity (AACG) -12%.Corvus Pharmaceuticals (CRVS) -10% after scrapping late-stage mupadolimab COVID-19 trialNeptune Wellness Sol...

Corvus Pharmaceuticals (CRVS) has discontinued its late-stage study of mupadolimab for COVID-19, citing positive trends shown by vaccines in lowering serious infection and hospitalizations.As of June 30, 2021, Corvus had cash, cash equivalents and marketable securities totaling about $66.5M.W...

Mupadolimab Phase 1/1b oncology clinical trial continues, with a focus on leveraging B cell activation and enhancement of anti-viral antibodies in an expansion cohort for patients with HPV+ (human papilloma virus) head and neck cancer Reduces projected 2021 net cash used in oper...

Corvus Pharmaceuticals ([[CRVS]] +4.1%) runs two clinical programs: Phase 3 study for the lead asset CPI-006 to treat hospitalized patients with COVID-19, CPI-818, a small molecule ITK inhibitor waiting for a Phase 2 trial in refractory peripheral T cell lymphoma ((PTCL)).The compan...

Vertex Energy (VTNR) +98% on deal for Shell's Mobile refinery.Moxian (MOXC) +37%.1847 Goedeker (GOED) +22%.SOS Limited (SOS) +14%.Bit Digital (BTBT) +13%.Vir Biotechnology (VIR) +9% as GSK/Vir COVID-19 biologic wins FDA Emergency Use Authorization.LAIX (LAIX) +12% on Q1 results...

BURLINGAME, Calif., May 25, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present at the Jefferies Virtual Healthcare Conference. The presentation will be on Thursday, June 3, 2021 from 4:00-4:2...

BURLINGAME, Calif., May 05, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that it has completed the sale of approximately $10 million of its common shares pursuant to the Company’s ATM program establis...